Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,…
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS…
Findings suggest a subset of Major Depressive Disorder patients may respond preferentially to vasopressin V1b receptor antagonismMUNICH, Oct. 13, 2025…
CHEYENNE, WYOMING / ACCESS Newswire / October 13, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) today announced the official launch of…
– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 –STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium…
MESA, AZ / ACCESS Newswire / October 13, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a diversified company advancing…
Phase 1 trial to investigate novel multi-specific HB2198 to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20…
Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and…
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform…
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis,…